CPOUF yields 6.81% · JNJ yields 2.13%● Live data
📍 CPOUF pulled ahead of the other in Year 1
Combined, CPOUF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CPOUF + JNJ for your $10,000?
Charoen Pokphand Foods Public Company Limited, together with its subsidiaries, engages in the agro-industrial and integrated food businesses in Thailand and internationally. It operates in two segments, Livestock Business and Aquaculture Business. The company produces and sells swine, chicken, cattle, duck, shrimp, and fish feeds; and breeds and farms swine, broiler, layer, duck, and shrimp. It is also involved in the animal feed raw materials distribution, investment and international trading, food products wholesale and retail, property investment, property lease-out, shrimp hatchery, and animal feedmill businesses. In addition, the company produces and distributes elite seeds, pet food, chlortetracycline, aquatic feed, sea food products, as well as motorcycle carburetor, auto parts, and plastic; and imports and distributes eggs, processed meat, milk products, and ready meals. Further, it offers economic and trade consulting, management and advisory, financial guarantee, biological waste management, information technology, food research and development, logistics, and financial services. Additionally, the company engages in the operation of food processing plants, hotels and restaurants, slaughterhouses, and training centers; broiler chicken integration business; provision and development of Asian food products; and swine farm construction activities. It provides its products primarily under the CP and Butcher brands. The company also exports its products. Charoen Pokphand Foods Public Company Limited was incorporated in 1978 and is headquartered in Bangkok, Thailand.
Full CPOUF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.